See how EMET powers the entire preclinical journey

Target Identification & Evidence

Literature synthesis, competitive intelligence, and target characterisation — the work that answers “is this worth pursuing?” before resources are allocated.

Literature Synthesis

Synthesizing a field in minutes, not days

Challenge

Reviewing the evidence base for a new target means scanning hundreds of papers, extracting experimental details, and reconciling conflicting findings across assay types and cell lines — a process that takes days and still produces a summary, not a structured evidence map.

What EMET delivers

A structured evidence synthesis across BenchSci’s curated corpus — with assay types, cell lines, experimental outcomes, and translatable biomarkers extracted and ranked. Completed before the next team meeting.

Target ID & Biology

3D structure, essentiality, and tissue liability — no specialist queue

Challenge

Running a complete target biology assessment — structure prediction, expression profiling, essentiality screening, and safety liability review — requires access to five different platforms, specialist bioinformatics support, and days of coordination before a scientist gets an answer.

What EMET delivers

AlphaFold structure with mutation impact highlighted, GTEx expression across 54 tissues, DepMap essentiality scores, and a conditional GO verdict — in a single conversation, without a bioinformatics queue.

Indication Expansion

Finding a second disease for an existing asset — before the competition does

Challenge

Identifying a credible new indication requires triangulating genetic evidence, shared disease biology, patient population overlap, existing clinical data, and competitive IP — a process that typically takes a translational team weeks and still produces a hypothesis rather than a scored recommendation.

What EMET delivers

EMET evaluated three candidate indications for a JAK inhibitor — scoring each on genetic evidence, pathway overlap, active trials, and competitive crowding — and returned a ranked scorecard with recommended next steps.

Translational Biology & Execution

Analytical pipelines, experimental troubleshooting, and omics interpretation — work that previously required specialist support or weeks of collaboration, completed in hours.

Omics & Pathway Analysis

Full multi-omics pipeline — no bioinformatics collaborator needed

Challenge

Wet-lab scientists with a GEO dataset face a bottleneck: getting DEG analysis, pathway enrichment, and TME deconvolution requires a bioinformatics collaborator with queue times measured in weeks, not days.

What EMET delivers

EMET executed the full pipeline — DESeq2 differential expression, Reactome pathway enrichment, CIBERSORT immune deconvolution — and returned a slide-ready summary with volcano plot and immune composition chart. No queue. No collaborator.

Experimental Optimization

Stalled for five months — unblocked in one week

Challenge

When a critical assay stops working, scientists spend weeks troubleshooting by trial and error — re-reading protocols, posting to forums, and running repeat experiments. The root cause is often buried in a methods section nobody indexed.

What EMET delivers

EMET cross-referenced the assay parameters against 400+ published protocols using the same antibody-cell line combination, identified a buffer pH incompatibility documented in two papers, and recommended a validated fix — confirmed working within the same week.

Safety, IND Readiness & Portfolio Decisions

Pre-IND safety profiling, regulatory screening, and stakeholder-ready outputs — the work that happens at the GO/NO-GO boundary, completed before it becomes the bottleneck.

Safety & Toxicology

Pre-IND safety profile — across every tissue, every regulatory database

Challenge

A thorough pre-IND target safety assessment spans essential gene screening, tissue expression liability, real-world adverse event signals, and known safety targets across multiple databases — typically requiring a dedicated safety pharmacologist and several days of coordinated analysis.

What EMET delivers

EMET returned a full safety scorecard — DepMap essentiality check, GTEx tissue liability panel, FAERS adverse event signal, and pathway safety flags — with a CONDITIONAL GO verdict and specific monitoring recommendations. Ready for the IND committee.

Drug-Drug Interaction

Screening a complex polypharmacy regimen before it reaches the clinic

Challenge

As combination therapies become standard of care, pharmacologists must screen every new compound against a patient’s existing medication list — checking CYP enzyme inhibition, transporter competition, QTc liability, and pharmacodynamic overlap across multiple disconnected databases.

What EMET delivers

EMET screened a five-drug oncology combination in a single query — identifying two major CYP3A4 interactions, a compounding QTc liability, and a contraindicated pairing flagged in the FDA label — with severity ratings, mechanistic explanations, and source citations for each finding.

Reporting & Stakeholder Communication

From raw analysis to board-ready package — in one step

Challenge

Translating a complex target validation analysis into a stakeholder-ready report requires reformatting outputs, rebuilding figures for presentation, writing executive summaries, and aligning on formatting across a team.

What EMET delivers

EMET generated a complete portfolio report — PDF with embedded figures, a 10-slide PowerPoint deck, and a live HTML dashboard with GO/NO-GO status — directly from the completed analysis. Formatted, cited, and ready to share in under five minutes.

Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.

Request a Demo